Praxis Precision Medicines reported positive Phase 3 results for its ulixacaltamide program in essential tremor, meeting primary endpoints in two studies and reversing a prior interim concern in one trial. The topline outcomes solidify ulixacaltamide’s efficacy signal for a disorder with limited medical options. The double win sent Praxis shares sharply higher as markets reassessed the company’s commercial prospects and probability of approval. Independent data monitoring had cast doubt earlier in the year, so the confirmatory readouts remove a key clinical execution risk and enable the company to plan regulatory next steps and potential commercialization strategy. Analysts and investors will now focus on detailed safety, responder rates, and label positioning versus current symptomatic treatments; successful regulatory filings could reposition Praxis in movement disorders and attract partner interest for late‑stage commercialization.